Korea’s SK Chemicals Looks To Sell First Generic Patch Of Novartis’ Exelon In Europe
This article was originally published in PharmAsia News
Executive Summary
SK Chemicals has signed a deal with 12 European pharmaceutical companies to sell its Alzheimer’s patch SID710, which it says, will be the first generic patch of Novartis’ Exelon in Europe.
You may also be interested in...
Korea's SK Biopharmaceuticals Quietly Sets Its Eyes On The U.S. - And China
SEOUL - After completion of preclinical trials with Chinese contract research organization Shanghai Medicilon Inc., Korea's SK Biopharmaceuticals Co. said Oct. 18 that it plans to file an Investigational New Drug application to conduct clinical trials in the U.S. - possibly in 2014 - for a compound to treat depression and manic bipolar disorder
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.